Clinical Efficacy and Prognostic Factors of Chemoreduction Combined with Topical Treatment for Advanced Intraocular Retinoblastoma

  • Liu, Yan (Nanjing University of Chinese Medicine) ;
  • Zhang, Xi (Russian Cancer Research Center of Russian Academy of Medical Sciences) ;
  • Liu, Fang (Nanjing University of Chinese Medicine) ;
  • Wang, Ke-Lei (Department of Ophthalmology, Wuxi Hospital of Traditional Chinese Medicine)
  • Published : 2014.10.11


Objective: To explore the clinical efficacy and prognostic factors of chemoreduction combined with topical treatment of advanced intraocular retinoblastoma (RB). Materials and Methods: A total of 22 eyes from 17 children with RB were selected for the study and treated with chemoreduction combined with topical cryotherapy, transpupillary thermotherapy (TTT) or episcleral plaque brachytherapy. Clinical and follow-up data were retrospectively analyzed. Results: All children received 2~6 courses of chemoreduction treatment, ($4.5{\pm}0.8$ courses on average); 17 eyes from 13 children were treated by chemoreduction combined with cryotherapy or TTT and 5 eyes from 4 children with chemoreduction combined with $^{125}I$ episcleral plaque brachytherapy. The eye retention rate was 81.8% (18/22), among which 38.9% (7/18) featured restored or maintained good vision. Postoperative follow-up period was 7 to 34 months, ($18.6{\pm}5.2$ months on average). The recurrence rate was 41.2% (7/17), among which 57.1% (4/7) were controlled by supplementing or appending cryotherapy or TTT treatment during the follow-up period. The tumor basal diameter and thickness were significantly reduced (P<0.05 or P<0.01) after treatment. All children demonstrated different degrees of hair loss, 70.6% (12/17) with different degrees of gastrointestinal reactions, 5.88% (1/17) with neutropenia and 11.8% (2/17) being seriously infected during the chemotherapeutic treatment. Univariate and logistic regression analysis showed that tumor basal diameter before treatment had a significant effect on the prognosis (P<0.01). Conclusions: Chemoreduction combined with topical therapy can effectively control RB in the short term, and tumor basal diameter before treatment is an independent risk factor for prognosis.


  1. Atchaneeyasakul L, Wongsiwaroj C, Uiprasertkul M, et al (2009). Prognostic factors and treatment outcomes of retinoblastoma in pediatric patients: a single-institution study. Jap J Ophthalmol, 53, 35-9.
  2. Aerts I, Sastre-Garau X, Savignoni A, et al (2013). Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol, 31, 1458-63.
  3. Balwierz W, Pietrys D, Romanowska-Dixon B, et al (2010). Results of combined chemotherapy and local ophtalmic therapy for intraocular retinoblastoma. Przegl Lek, 67, 404-8.
  4. Berry JL, Jubran R, Kim JW, et al (2013). Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer, 60, 688-93.
  5. Huang D, Zhang Y, Zhang W, et al (2013). Study on clinical therapeutic effect including symptoms, eye preservation rate, and follow-up of 684 children with retinoblastoma. Eur J Ophthalmol, 23, 532-8.
  6. Khan ZN, Sabir M, Kayani MA, et al (2013). Acetylation of retinoblastoma like protein2 (Rb2/p130) in tumor tissues. Asian Pac J Cancer Prev, 14, 2255-8.
  7. Kim JM, Kim JH, Kim SJ, et al (2010). Visual prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy plus local treatments. Korean J Ophthalmol, 24, 347-52.
  8. Künkele A, Jurklies C, Wieland R, et al (2013). Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre. Br J Ophthalmol, 97, 1277-83.
  9. Lambert MP, Shields C, Meadows AT (2008). A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer, 50, 223-6.
  10. Li J, Xu ZW, Wang KH, et al (2013). Networks of MicroRNAs and genes in retinoblastomas. Asian Pac J Cancer Prev, 14, 6631-6.
  11. Peterson EC, Elhammady MS, Quintero-Wolfe S, et al (2011). Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors: Clinical article. J Neurosurg, 114, 1603-8.
  12. Shields CL, Honavar SG, Meadows AT, et al (2002). Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol, 133, 657-64.
  13. Shields CL, Shelil A, Cater J, et al (2003). Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol, 121, 1571-6.
  14. Shields CL, Shields JA (2010). Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol, 21, 203-12.
  15. Shin JY, Kim JH, Yu YS, et al (2010). Eye-preserving therapy in retinoblastoma: prolonged primary chemotherapy alone or combined with local therapy. Korean J Ophthalmol, 24, 219-24.
  16. Srivastava V, Patel B, Kumar M, et al (2013). Cyclin D1, retinoblastoma and p16 protein expression in carcinoma of the gallbladder. Asian Pac J Cancer Prev, 14, 2711-5.
  17. Turaka K, Shields CL, Meadows AT, et al (2012). Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer, 59, 121-5.

Cited by

  1. Intra-Arterial Chemotherapy as Primary Therapy for Retinoblastoma in Infants Less than 3 Months of Age: A Series of 10 Case-Studies vol.11, pp.8, 2016,